Haemonetics Corporation (NYSE:HAE) Shares Acquired by Royce & Associates LP

Royce & Associates LP boosted its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 0.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,161,296 shares of the medical instruments supplier’s stock after purchasing an additional 8,028 shares during the period. Haemonetics makes up approximately 0.8% of Royce & Associates LP’s holdings, making the stock its 8th biggest position. Royce & Associates LP’s holdings in Haemonetics were worth $73,800,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in HAE. HighTower Advisors LLC boosted its stake in shares of Haemonetics by 7.8% during the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier’s stock valued at $262,000 after buying an additional 244 shares during the period. Natixis Advisors LLC bought a new position in Haemonetics in the 4th quarter worth $1,194,000. Xponance Inc. grew its position in Haemonetics by 5.9% in the 4th quarter. Xponance Inc. now owns 7,246 shares of the medical instruments supplier’s stock worth $566,000 after purchasing an additional 404 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Haemonetics in the 4th quarter worth $345,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Haemonetics in the 4th quarter worth $789,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

HAE has been the topic of several recent research reports. Raymond James Financial reiterated a “strong-buy” rating and set a $105.00 target price (down from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Baird R W raised shares of Haemonetics to a “strong-buy” rating in a research note on Wednesday, June 25th. Needham & Company LLC dropped their price target on shares of Haemonetics from $104.00 to $84.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. Citigroup raised shares of Haemonetics from a “neutral” rating to a “buy” rating and set a $90.00 price target for the company in a research note on Wednesday, July 9th. Finally, Wall Street Zen cut shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Haemonetics currently has an average rating of “Moderate Buy” and a consensus price target of $97.30.

Haemonetics Stock Performance

HAE stock traded down $0.56 during trading hours on Thursday, reaching $74.01. The stock had a trading volume of 59,667 shares, compared to its average volume of 748,868. The stock has a market capitalization of $3.56 billion, a PE ratio of 22.36, a price-to-earnings-growth ratio of 1.20 and a beta of 0.39. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.62 and a quick ratio of 0.99. The stock has a 50-day simple moving average of $71.93 and a 200 day simple moving average of $67.84. Haemonetics Corporation has a fifty-two week low of $55.30 and a fifty-two week high of $94.99.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.02. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. The company had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. During the same period in the prior year, the firm earned $0.90 earnings per share. The company’s revenue was down 3.5% on a year-over-year basis. Analysts predict that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.